Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Taro Pharmaceutical's Brampton manufacturing facility, following the re-scrutiny of the site after February 2011.
Subscribe to our email newsletter
Taro Pharma is a pharmaceutical company engaged in the discovery, development, manufacturing and marketing of the healthcare products.
Earlier, FDA issued warning letter to the company in connection with its Canadian manufacturing facility on 5 February 2009.
Taro Pharma interim CEO James Kedrowski said they have worked diligently at the Brampton facility to resolve the issues noted in the last inspection and are pleased that their efforts have brought the facility back into good standing with the Agency.
"We are dedicated to developing and manufacturing quality products for our customers while meeting and exceeding all Good Manufacturing Practices (GMP) standards set by the FDA and Health Canada," Kedrowski said.